OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Check out the latest features and columns!
March's Executive Profile features Davidek Herron, Global Head of Digital, Roche
Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day
Pharm Exec's 18th Annual Pipeline Report focuses on spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics
March 13, 2023
Pfizer will pay pay $229 a share in cash for the cancer specialist.
Acquisition will bolster Sanofi's work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks.
Sumitovant Biopharma has completed its acquisition of Myovant Sciences in an all-cash deal worth $1.7 billion, with Myovant being delisted from the New York Stock Exchange and its shares no longer publicly traded.
March 10, 2023
As the life sciences industry enters this next stage of growth, capitalizing on AI and digital transformation will be key to propelling innovation and ensuring that companies are prepared to tackle the challenges ahead.
While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.
The importance of not over-expanding during development, launch.
Global medical affairs teams seek better support to manage relationships with key opinion leaders—and find that balance between patient needs, scientific objectives, and the interest areas of KOLs.
How pharma companies can leverage the lessons learned during the pandemic around key opinion leaders and digital opinion leaders, respectively, to best use new channels of communication. Can both coexist across the healthcare engagement spectrum?
Manufacturer to withdraw preterm birth drug, amid latest FDA push.
The rise of DOLs doesn’t mean pharma should upend KOL approach.